Atezolizumab (anti-programmed death-ligand 1 (PD-L1)) and bevacizumab (anti-vascular
endothelial growth factor (VEGF)) combination therapy has become the new standard of …

Hepatocellular carcinoma (HCC) is a common cancer globally and a leading cause of
cancer-related deaths. Although early-stage disease may be curable by resection, liver …

4074 Background: Advanced HCC is a lethal cancer with a high unmet medical need. Single-
agent immunotherapy with PD-L1/PD-1 blockade or treatment (Tx) with anti-angiogenic …

Background Dual blockade of PD-L1 and VEGF has enhanced anticancer immunity through
multiple mechanisms and augmented antitumour activity in multiple malignancies. We …

Background: Agents targeting angiogenesis or PD-L1/PD-1 signalling represent 2 types of
approved treatments (tx) for HCC. In addition to its anti-angiogenic activity, bevacizumab …

Advanced hepatocellular carcinoma (HCC) patients present poor prognosis. However,
recent years have seen the advent of several novel treatments in this setting, where the role …

A successful phase III trial for the combination of atezolizumab and bevacizumab (the
IMbrave150 trial) in advanced hepatocellular carcinoma has recently been reported. This is …

Background The combination of atezolizumab and bevacizumab showed encouraging
antitumor activity and safety in a phase 1b trial involving patients with unresectable …

More than a decade ago, sorafenib became the first systemic therapy that conferred a
meaningful survival benefit in the treatment of advanced hepatocellular carcinoma. 1 Since …

Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading
cause of cancer-related death and its incidence is increasing globally. Around 50% of …